Answers are grounded in this paper and cite their sources.
Neurofibroma development was not prevented by MEK inhibition, beginning at 1 month of age, but tumor size was controlled by early treatment. Moreover, treatment with PD-0325901 at very low doses may shrink neurofibromas while minimizing toxicity. These studies highlight how genetically engineered mouse models can guide clinical trial design.
No takes yet. Share an insight, caveat, or question.
Jousma et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: